Back

Pharma

8th Impurities: Genotoxic, Nitrosamine, & Beyond Summit

  • 10th – 11th April 2024
  • Austria flag Austria Vienna & Online

The recall of Valsartan has underscored the critical necessity for a rational risk assessment strategy regarding potential nitrosamines in pharmaceutical products.

At the #VLgenotoxic 2024 event, our focus will not only be on N-nitrosamines but also on exploring key aspects related to the detection and reporting of genotoxic impurities (GTIs). We will delve into current investigations, regulatory considerations, toxicological assessments, analytical methodologies, and pharmaceutical relevance pertaining to GTIs. Additionally, we will discuss recent advancements, ongoing developments, and future considerations regarding various types of impurities found in pharmaceuticals.

Join us for enlightening keynote presentations, insightful case studies, engaging panel discussions, interactive Q&A sessions, and a chance to explore exhibitions. This conference will also provide ample opportunities to foster partnerships while gaining valuable insights into advanced strategies and perspectives within the realm of impurities and extractables and leachables (E&L). Save the date for the 8th Impurities: Genotoxic, Nitrosamine, & Beyond conference, taking place on April 10-11, 2024.

Read more

About the 8th Impurities: Genotoxic, Nitrosamine, & Beyond Summit (#VLgenotoxic)

The Valsartan recall, attributed to the presence of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) impurities in widely prescribed pharmaceuticals, has initiated dynamic developments in the pharmaceutical landscape, yielding several key insights:

  • The imperative need for investigating potential N-nitrosamine contamination and its mutagenic and carcinogenic risks to patients.
  • Withdrawals, recalls, and clinical trial delays involving drugs such as ranitidine, nizatidine, metformin, rifampin/rifapentine, varenicline, and others.
  • The critical importance of formulating a rational risk-assessment strategy to avoid both overestimation and underestimation of nitrosamine-related risks in pharmaceutical products.

Critical issues and lessons gleaned from the Valsartan incident encompass:

  • Identification of potential gaps in current pharmaceutical practices that may divert attention from FDA and drug manufacturers concerning NMDA and NDEA impurities.
  • Recent strategies and acceptable intake (AI) thresholds for nitrosamine impurities.
  • Application of nitrosamine formation in risk assessment during pharmaceutical processes, encompassing drug substance (DS), drug product (DP), and drug product packaging (DPP).
  • The need for pharmaceutical experts, in collaboration with researchers, academia, and toxicologists, to generate knowledge and methodologies shaping future regulations for controlling N-nitrosamines as mutagenic impurities in pharmaceuticals.
  • The establishment of control strategies to minimise nitrosamine impurity presence, optimise manufacturing processes, and mitigate the carcinogenic risk to patients.
  • The collaborative involvement of various stakeholders, including active pharmaceutical ingredient (API) manufacturers, excipient providers, primary packaging suppliers, and drug product manufacturers, due to the complexity of risk analysis.

At the #VLgenotoxic 2024 event, our focus will extend beyond N-nitrosamines, covering the following key areas:

  • Illuminating crucial aspects of detecting and reporting genotoxic impurities in the pharmaceutical industry.
  • Exploring ongoing investigations and addressing regulatory, toxicological, analytical, and pharmaceutical considerations related to genotoxic impurities (GTIs).
  • Assessing the impact of implementing ICH M7 guidelines, offering guidance on the hazard identification and risk assessment process for genotoxic impurities in pharmaceuticals.
  • Discussing relevant guidelines to prevent N-nitrosamine contamination in human medicines and alternative strategies for initial risk evaluation and confirmatory testing of drug products and APIs susceptible to N-nitrosamine formation.
  • Continuing to explore recent advancements, further developments, and future considerations concerning various types of impurities found in drugs, including genotoxic impurities, nitrosamines, elemental impurities, extractables, leachables, and others.

The forward-looking 8th Impurities: Genotoxic, Nitrosamine, & Beyond Summit, scheduled for April 10-11, 2024, will be hosted by leading experts in the genotoxic and elemental impurities field.

Join us for keynote presentations, insightful case studies, interactive panel discussions, and Q&A sessions. Explore exhibitions and seize partnership opportunities while gaining valuable insights into advanced strategies and perspectives in the realm of impurities and extractables and leachables (E&L).

Engage in comprehensive presentations, technical training, and workshops, delving into recent advancements and challenges related to:

  • Practical regulatory and toxicological considerations for efficient identification, monitoring, and control of mutagenic impurities (ICH M7).
  • Critical issues and lessons learned concerning the quality, safety, and efficacy of drug products.
  • Addressing uncertainties and misalignments in nitrosamine safety assessments.
  • Regulatory requirements and perspectives on nitrosamines.
  • Recent experiences with E&L and elemental impurities (ICH Q3D).

A digital certificate of attendance will be provided to #VLgenotoxic participants.

Who Should Attend:

Chief Executives, Vice Presidents, Directors, Heads, Leaders, and Managers specialising in:

  • Analytical Science
  • API Development
  • Assay Development
  • Biotherapeutics
  • Carcinogenic Impurities
  • Carcinogenicity
  • Carcinogens
  • Chemistry (Analytical, Organic, Medicinal, Protein)
  • Chromatography
  • Degradation Products
  • DNA Reactive Impurities
  • DNA Reactivity
  • Drug Design
  • Drug Development
  • Drug Discovery
  • Drug Safety
  • Drug Substance
  • Elemental Impurities
  • Extractables & Leachables
  • Formulation
  • Genetic Toxicology
  • Genotoxic Impurities (GTI)
  • Genotoxicity
  • Genotoxin
  • GMP
  • Good Laboratory Practice
  • GRAs
  • GTIs
  • Impurities
  • In Silico
  • Large Molecule
  • LC-MS
  • Mass Spectrometry
  • Microscopy
  • Mutagenic Impurities
  • Mutagenicity
  • Nanomaterials
  • Nanoparticles
  • New Modality
  • Oligonucleotide
  • Organic Synthesis
  • Particles
  • Peptide
  • Potential Genotoxic Impurities (PGTIs)
  • Preclinical Drug Safety
  • Process Chemistry
  • Process-Related Impurities
  • Product-Related Impurities
  • Protein
  • Purification
  • Purge Factors
  • Quality Assurance (QA)
  • Quality By Design (QbD)
  • Quality Control (QC)
  • Regulatory
  • R&D
  • Safety Assessment
  • Small Molecule
  • Spectroscopy
  • Total Daily Intake (TDI)
  • Technology Transfer
  • Threshold of Toxicological Concern (TTC)
  • Toxicology
  • Validation

Register by December 15th

The Early Bird Offer expires in 8 days!

REQUEST A BROCHURE

To request an agenda for this Summit, please complete the details below. We will send you the agenda via email.

Key Practical Learning Points

  • Critical factors for maintaining compliance when implementing ICH M7 and Q3D guidelines
  • Effective control of DNA-reactive N-nitrosamine impurities to mitigate potential carcinogenic risks
  • Navigating uncertainties, resolving misalignments, and benefiting from insights related to nitrosamines
  • Exploring cutting-edge techniques, technologies for the identification, monitoring, and control of GI
  • Advancing risk assessment and exploring guidance on the safe qualification of impurities
  • Addressing potential gaps that impact the identification and control of mutagenic impurities
  • Navigating genotoxic impurities CMC regulations, potential pitfalls, and industry expectations
  • Assessment, testing, and control of impurities in pharm products, drug substances/APIs, and excipients
  • Thorough evaluation of E&L to assess genotoxicity risks and guarantee comprehensive safety assessments
  • Updates, future prospects, and insights on analytical techniques, regulatory, and toxicology science

Register by December 15th

The Early Bird Offer expires in 8 days!

Dr. Andrew Teasdale, UK

Senior Principal Scientist / Head of Impurity Management & CMC Strategy

AstraZeneca

Andrew Teasdale, PhD, is a senior principal scientist in impurity management and external advocacy at AstraZeneca. Andrew has over 20 years’ experience in the pharmaceutical industry as an analytical chemist and within quality assurance and regulatory roles. In his current role, he chairs AstraZeneca’s impurity advisory group. Andrew has published over 30 papers relating to genotoxic impurities and other impurity-related matters and has been a speaker at many international conferences. He has also led a number of industry expert groups; these include both safety and quality groups within Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Product Quality Research Institute (PQRI), and the Extractables and Leachables Safety Information Exchange (ELSIE). Andrew led the recent development of the ICH M7 addendum table from an industry perspective and was the inventor of the purge tool concept, Mirabilis™. He also published a book addressing genotoxic impurities, ‘Genotoxic Impurities Strategies for Identification and Control,’ (Wiley and Son) and is soon to publish as editor a book focussed on practical implementation of ICH quality guidelines.

Dr. Raphael Nudelman, IL

Senior Director of Impurity Expert, R&D Operations

Teva Pharmaceutical Industries Ltd.

Raphael Nudelman holds a master's of pharmaceutical sciences from the Hebrew University of Jerusalem and a PhD in organic chemistry from the Weizmann Institute of Science in Rehovot, Israel. He held research fellow positions in the US Air Force Research Lab in Aberdeen Proving Ground, Maryland, USA, and at the Duke University Medical Center, North Carolina, USA. He has been with Teva Pharmaceutical Industries in Israel since 2003 and held research positions in the medicinal chemistry department and the patent department. Since 2010, he has been the head of chemical and computational toxicology in Teva's non-clinical safety department. From 2011-16, Raphael also served as the president of the medicinal chemistry section of the Israel Chemical Society.

Dr. Susanne Glowienke, CH

Director, Preclinical Safety

Novartis Pharma AG

Dr. Susanne Glowienke graduated from the University of Stuttgart-Hohenheim, Germany, in food chemistry/technology. She then undertook research in the area of analytical chemistry and obtained her PhD degree from the faculty of food technology (cereal chemistry) in 1997 at the same university. In 2000, she joined Novartis in Basel, Switzerland, as a postdoc in the area of Q(SAR) for toxicological endpoints. Susanne was working as a lab head for bacterial mutagenesis in genetic toxicology, preclinical safety and is responsible for the QSAR predictions and impurity/excipient assessments at Novartis. 

Currently, Susanne is a director in preclinical safety at Novartis, Basel, Switzerland. She held several positions at Novartis, including positions in genetic toxicology and QSAR modelling. She is currently head of the impurity safety group and as such responsible for contaminant issues including nitrosamines. Susanne is part of and has led a number of industry expert groups within DruSafe IQ (US), European Federation of Pharmaceutical Industries and Associations (EFPIA), the Extractables and Leachables Safety Information Exchange (ELSIE), and several data sharing initiatives.

Dr. Alexander Amberg, DE

Head of In Silico Toxicology / R&D Preclinical Safety FF

Sanofi Aventis Deutschland GmbH

Alexander Amberg performed his doctoral studies at the department of toxicology and pharmacology at the University of Wuerzburg (Germany) and obtained his PhD in biochemical toxicology in 2000. In 2001, he joined the early and exploratory safety group of Sanofi, and in this position has been responsible for in silico/computational toxicology analysis globally at Sanofi. Since 2007, he has been registered as a European registered toxicologist (ERT) after getting his examination of Fachtoxikologe DGPT from the German Society of Toxicology. His major research interests are development of new in silico prediction models for different toxicity endpoints and data management of in-house data in combination with publicly available toxicity data, to support drug development in research and development. For this he is also a member of different internal expert advisory groups as well as external initiatives, like the IMI eTOX consortium (for toxicity data sharing and development of new expert systems for in silico toxicity prediction), the IMI SafeSciMET education program and others. With respect to genotoxic impurities (GTIs), he was actively involved in the preparation of the white paper for the use of in silico systems in the scope of ICH M7 and other publications regarding GTIs. Internally, he is member of the task force to support the in-house implementation of ICH M7.

Dr. Kausik K Nanda, US

Principal Scientist

MSD (Merck Sharp & Dohme Corp.)

Kausik Nanda has more than 23 years of experience in the pharmaceutical industry. In his early career as a medicinal chemist, Kausik worked on discovery programs in the neuroscience, cardiovascular, and infectious disease areas, where his team successfully developed lead identification, lead optimisation, and pre-clinical candidates. In his later career, Kausik’s work focussed on solving a multitude of problems in the development area, arising from chemical interaction in the drug product. Primarily, Kausik’s work focusses on drug degradation, mutagenic impurities, nitrosamine risk assessment and novel formulations inhibiting nitrosamine formation. The range of activities encompasses early development through commercial launch.

Dr. Rok Grahek, SL

Department Head

SDC Slovenia, Lek d.d., Sandoz

Rok Grahek received his BSc in chemistry and his PhD in science from the University of Ljubljana, Slovenia.

In 1986, Rok was employed in R&D in Lek Pharmaceuticals d.d. Slovenia.

As a researcher he started with GC and after a few years HPLC and MS became his main area of interest in connection with impurities in drugs. Trace analysis of impurities (genotoxic impurities, synthetic tracers, nitrosamines) with LC-MS and GC-MS is an important area of Rok’s research. For the past 25 years, Rok has been leading a group or researchers dealing mainly with impurity profiles, impurities isolation, identification, and trace analytics.

Rok is an author or co-author of nearly 40 patents and scientific papers and more than 50 scientific conference contributions.

Dr. Lutz Mueller, CH

Chair Translational Safety Committee Pharma Research and Early Development (pRED)

Hoffmann-La Roche

Dr. Lutz Mueller started his career with moving into genetic toxicology in 1981 when starting to work on his Diploma in biology. This means that he has accrued in the meantime about 40 years of experience in safety assessment of medicines. From 1989 on, he has been the head of the department of Mutagenesis and Carcinogenesis at the Federal Institute for Drugs and Medical Devices in Berlin, Germany. In 2000, he moved into industry to create a group of entrepreneurs working on “In silico Safety and Metabolism” at Novartis in Basel. While at Novartis, he began to realize the power of working with project leader responsibilities in Oncology. In late 2004, he moved to F. Hoffmann-La Roche into the role of a toxicology project leader and has ever increased his area of expertise in toxicology and safety assessment ever since. Small molecules, antisense modalities, biologics and vector-based gene therapy products for new medicines for human disease, he has worked on them all. He has also served as liason between safety assessment and research at Roche for neuroscience, ophthalmology and rare diseases establishing and tightening the close relationships between research and development in drug discovery. While he has contributed at Roche to move many molecules into man and further along the clinical development phase even into approval, the big reward came in Mid 2020 with the approval for the world’s first small molecule mRNA splice modifier, risdiplam. He has been a major driving force behind the fast R&D process on this medicine named Evrysdi to help patients with spinal muscular atrophy. Lutz Mueller is currently chairing the corporate Translational Safety Committee of Roche’s Pharma Research and Early Development function. His internal and external reputation is evidently documented with the title of “distinguished scientist” and supported by his contribution to more than 100 peer reviewed publications and book chapters. Moreover, he left his mark in the international contribution in the ICH guideline process since 1991, the inception of the ICH process. Still today, he is representing EFPIA on ICH M7, the “mutagenic impurities” guideline. He also earned his reputation being a frequent presenter at international conferences.

Dr. Jacky Van Gompel, BE

Business Owner

MoonWave Consulting

Dr. Carla Landolfi, IT

European Registered Toxicologist (ERT) CEO - Toxicology Risk Assessor

ToxHub

Dr. Carla Landolfi graduated in chemistry and pharmaceutical technology from Rome University. She has more than 20 years of experience in the toxicology field gained in the pharmaceutical industry, 10 of them as manager to the toxicology group. She's the main or co-author of several papers and posters, has published in peer-reviewed journals, and she's an invited speaker at international conferences as well as the founding editor of archives of clinical toxicology. In 2020, she founded the ToxHub, a consultancy company specialised in toxicological risk assessment and regulatory toxicology.

Dr. George Johnson, UK

Associate Professor

Institute of Life Science at Swansea University

George Johnson is an associate professor of genetic toxicology at Swansea University. He has expertise in the quantitative use of genetic toxicity data for hazard and risk assessment purposes and has an interest in high content and multiplex in-vitro test systems. He currently has active roles in the HESI-GTTC, IWGT 2022, COM and EEMGS-EXCOM, and carries out teaching, research, and consultancy at Swansea.

Dr. Markus Obkircher, DE

Director, Research & Development

Merck Life Science

Markus Obkircher is director of R&D, heading Merck’s reference materials and proficiency testing division with teams in the US and Switzerland. He is responsible for the in-house development of new analytical standards and certified reference materials under ISO/IEC 17025 and ISO 17034 double accreditation. Prior to this position he was R&D manager in Buchs, Switzerland, with a strong focus on synthesis, characterisation, and certification of reference materials. He joined Merck/Sigma-Aldrich eight years ago after heading the development unit for a custom API manufacturer. He completed his post-doctoral studies at Harvard in Boston and his PhD thesis in Basel, and further holds an executive MBA degree from the University of Zurich.

Dr. Paulo Eliandro da Silva Junior, BR

Technical and Regulatory Director

INTEGRA CONSULTANCY

Dr. Paulo Eliandro da Silva Junior is a pharmacist-biochemist (USP) with a master's and PhD in medicinal chemistry, synthesis and drug discovery (FCFRP-USP, University of East Anglia – UEA, UK; Johannes Gutenberg University of Mainz – JGU, Germany). Paulo's experience in the pharmaceutical industry started in 2013 as a trainee at Novartis, Horsham, UK, in the global discovery chemistry department. After that Paulo worked mainly in regulatory affairs, quality audits, and drug product and drug substance development with focus on impurities control, including E&L, mutagenic impurities, such as nitrosamines, in his own consulting company, Integra Consultancy. Paulo also is a founder of another company, BIND, which is a startup for synthesis and characterisation of analytical standard for development processes, and teaches postgraduate courses that cover various pharmaceutical topics.

Dr. Marko Trampuž, SL

Scientist, Early Development

SDC Slovenia, Lek d.d., Sandoz

Dr. Marko Trampuž works as a scientist in the early development department in Sandoz Development Centre Slovenia, Lek Pharmaceuticals d.d. He obtained his MPharm degree in 2015 and PhD in chemical sciences in 2019 at the University of Ljubljana in Slovenia. His PhD research work focussed on particle engineering, polymorphism, and mathematical modelling of chemical processes, particularly crystallisation. After completing his PhD, he worked as a medicinal chemist at drug discovery and development platform in SciLifeLab in Stockholm, Sweden, specialising in drug discovery of novel drugs for psychiatric, autoimmune, and oncological disorders. Since joining Lek Pharmaceuticals d.d. in 2021, his main responsibilities have been the development of novel analytical approaches for N-nitrosamine impurities and complex APIs, utilising his skills in synthetic organic chemistry and various spectroscopic methods.

Dr. Andrew Teasdale, UK

Senior Principal Scientist / Head of Impurity Management & CMC Strategy

AstraZeneca

Dr. Raphael Nudelman, IL

Senior Director of Impurity Expert, R&D Operations

Teva Pharmaceutical Industries Ltd.

Dr. Susanne Glowienke, CH

Director, Preclinical Safety

Novartis Pharma AG

Dr. Alexander Amberg, DE

Head of In Silico Toxicology / R&D Preclinical Safety FF

Sanofi Aventis Deutschland GmbH

Dr. Kausik K Nanda, US

Principal Scientist

MSD (Merck Sharp & Dohme Corp.)

Dr. Rok Grahek, SL

Department Head

SDC Slovenia, Lek d.d., Sandoz

Dr. Lutz Mueller, CH

Chair Translational Safety Committee Pharma Research and Early Development (pRED)

Hoffmann-La Roche

Dr. Jacky Van Gompel, BE

Business Owner

MoonWave Consulting

Dr. Carla Landolfi, IT

European Registered Toxicologist (ERT) CEO - Toxicology Risk Assessor

ToxHub

Dr. George Johnson, UK

Associate Professor

Institute of Life Science at Swansea University

Dr. Markus Obkircher, DE

Director, Research & Development

Merck Life Science

Dr. Paulo Eliandro da Silva Junior, BR

Technical and Regulatory Director

INTEGRA CONSULTANCY

Dr. Marko Trampuž, SL

Scientist, Early Development

SDC Slovenia, Lek d.d., Sandoz

BROCHURE

Request the 8th Impurities: Genotoxic, Nitrosamine, & Beyond Summit brochure and find out the latest topics and ideas that will be shared.

Request

Please fill in your e-mail address below and we will process your request in a moment.

What our
participants
are saying

Attending the #VLgenotoxic Summit was a game-changer for me. The depth of knowledge and expertise shared by the speakers and panellists was unparalleled. I left with a clearer understanding of the earliest practices related to genotoxic impurities and their impact on pharmaceuticals. This event is a must for anyone in the industry who wants to stay ahead of the curve.

1
2
3
4
5

PREVIOUS

Attendee

The #VLgenotoxic exceeded all my expectations. The sessions were not only informative but also highly engaging. The discussions on nitrosamine contamination and its regulatory implications were particularly insightful. I left the summit with valuable insights and practical strategies that I could immediately apply to my work.

1
2
3
4
5

PREVIOUS

Attendee

I had the privilege of attending the #VLgenotoxic Summit, and it was truly enlightening. The diverse range of topics covered, from genotoxic impurities to E&L considerations, provided a comprehensive overview of the challenges faced by the pharmaceutical industry. The networking opportunities were also fantastic, allowing me to connect with experts in the field. I can't wait for the next summit!

1
2
3
4
5

PREVIOUS

Attendee